Search results
Produce a new standalone guideline on uncontrolled asthma that includes guidance on pharmacological management (specifically biologics), assessment, phenotyping, high-risk patients, biomarkers and monitoring (replacing the existing sections 7 and 10).
BTS/SIGN British Guideline on the Management of Asthma. BTS/SIGN/NICE joint Guideline for the Diagnosis, Monitoring and Management of Chronic Asthma. The draft guideline, evidence reviews and information on the consultation on the guideline is here.
the Scottish Intercollegiate Guidelines Network (SIGN) about the care and treatment of children with asthma. The clinical guideline is based on what we know from current medical research. It also gives advice based on the opinion of healthcare professionals who are trained on how best to treat your child’s asthma.
SIGN 158 British guideline on the management of asthma. Recommendations are graded A B C D to indicate the strength of the supporting evidence. Good practice points are provided where the guideline development group wishes to highlight specific aspects of accepted clinical practice.
practice in the management of asthma. It makes recommendations on management of adults, including pregnant women, and adolescents and children with asthma. In sections 7 and 8 on pharmacological management and inhaler devices, respectively, and in section 4.3 on predicting future risk of asthma attacks, each
Children and young people exposed prenatally to alcohol (SIGN 156) Child abuse and neglect (NICE NG76) End of life care for infants, children and young people with life-limiting conditions: planning and management (NICE NG61)
This is a new collaborative guideline produced by BTS, NICE and SIGN. It updates NICE guideline 80 (published November 2017) and parts of BTS/SIGN guideline (SIGN 158, published July 2019). Who is it for? • GPs and practice nurses • Healthcare professionals in secondary care and tertiary asthma services • Commissioners and providers
